News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Suresh S. Ramalingam, MD, Winship Cancer Institute

Articles by Suresh S. Ramalingam, MD, Winship Cancer Institute

The Future of Lung Cancer Treatment

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Fundamentals of Mesothelioma

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Latest Updated Articles

Trials in Limited-Stage Small-Cell Lung Cancer
Published: October 26th 2020 | Updated:
Fundamentals of Mesothelioma
Published: October 26th 2020 | Updated:
Recent Advances in Small-Cell Lung Cancer
Published: October 26th 2020 | Updated:
Understanding Immune Response in Non–Small Cell Lung Cancer
Published: October 26th 2020 | Updated:
Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer
Published: October 26th 2020 | Updated:
Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer
Published: October 26th 2020 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies